CD38
ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
Also known as: cADPR1, CD38_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P28907
- Gene
- CD38
- Ensembl
- ENSG00000004468
- Chromosome
- 4
- Canonical length
- 300 aa
- Protein class
- Cancer-related genes, CD markers, Enzymes, Metabolic proteins, Predicted intracellular proteins
- Subcellular location
- Plasma membrane
- Quaternary structure
- Homodimer
OverviewNCBI Gene
The protein encoded by this gene is a non-lineage-restricted, type II transmembrane glycoprotein that synthesizes and hydrolyzes cyclic adenosine 5'-diphosphate-ribose, an intracellular calcium ion mobilizing messenger. The release of soluble protein and the ability of membrane-bound protein to become internalized indicate both extracellular and intracellular functions for the protein. This protein has an N-terminal cytoplasmic tail, a single membrane-spanning domain, and a C-terminal extracellular region with four N-glycosylation sites. Crystal structure analysis demonstrates that the functional molecule is a dimer, with the central portion containing the catalytic site. It is used as a prognostic marker for patients with chronic lymphocytic leukemia. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2015]
Canonical amino-acid sequenceUniProt
300 residues, UniProt reviewed canonical sequence.
>P28907|CD38
1 MANCEFSPVS GDKPCCRLSR RAQLCLGVSI LVLILVVVLA VVVPRWRQQW SGPGTTKRFP
61 ETVLARCVKY TEIHPEMRHV DCQSVWDAFK GAFISKHPCN ITEEDYQPLM KLGTQTVPCN
121 KILLWSRIKD LAHQFTQVQR DMFTLEDTLL GYLADDLTWC GEFNTSKINY QSCPDWRKDC
181 SNNPVSVFWK TVSRRFAEAA CDVVHVMLNG SRSKIFDKNS TFGSVEVHNL QPEKVQTLEA
241 WVIHGGREDS RDLCQDPTIK ELESIISKRN IQFSCKNIYR PDKFLQCVKN PEDSSCTSEILocalizationUniProt · AlphaFold · HPA
Whether an antibody against CD38 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.31
- Highest tissue expression
- 59 nTPM
Expression across tissuesHPA
Tissue
- thymus: 59 nTPM
- lymph node: 22 nTPM
- skeletal muscle: 20 nTPM
- seminal vesicle: 19 nTPM
- tonsil: 17 nTPM
- spleen: 16 nTPM
Single-cell type
- plasma cells: 469 nCPM
- megakaryocyte-erythroid progenitors: 279 nCPM
- astrocytes: 201 nCPM
- hematopoietic stem cells: 197 nCPM
- megakaryocyte progenitors: 178 nCPM
- respiratory ciliated cells: 168 nCPM
Immune cell
- NK-cell: 18 nTPM
- memory B-cell: 9.9 nTPM
- naive B-cell: 7.7 nTPM
- plasmacytoid DC: 5.8 nTPM
- myeloid DC: 4.7 nTPM
- total PBMC: 4.4 nTPM
Brain region
- hypothalamus: 15 nTPM
- midbrain: 14 nTPM
- white matter: 11 nTPM
- thalamus: 9.7 nTPM
- basal ganglia: 9.2 nTPM
- hippocampal formation: 8.8 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about CD38.
Disease | AutoantibodyPubMed
Conditions in which antibodies against CD38 are reported. Each links to that disease's full target list.
ReferencesPubMed · IEDB
Publications for CD38 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
46 publications
- BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells.
2025 · Nat Med · RCR 17.4 · 57 citations - A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia.
2024 · N Engl J Med · RCR 7.3 · 46 citations - Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease.
2024 · Blood Adv · RCR 6.3 · 28 citations - Daratumumab for treatment-refractory antibody-mediated diseases in neurology.
2022 · Eur J Neurol · RCR 6 · 65 citations - Successful Rescue Therapy With Daratumumab in Rapidly Progressive Interstitial Lung Disease Caused by MDA5-Positive Dermatomyositis.
2023 · Chest · RCR 4.7 · 37 citations
Show 20 more of 46 total
- Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy.
2024 · Kidney Int Rep · RCR 4.2 · 23 citations - Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease.
2024 · Lupus Sci Med · RCR 3.6 · 22 citations - Daratumumab for immune thrombotic thrombocytopenic purpura.
2022 · Blood Adv · RCR 3.3 · 33 citations - B cells and antibodies in refractory immune thrombocytopenia.
2023 · Br J Haematol · RCR 3.2 · 27 citations - Daratumumab treatment for therapy-refractory anti-CASPR2 encephalitis.
2020 · J Neurol · RCR 2.8 · 56 citations - Daratumumab as a novel treatment option in refractory ITP.
2023 · Blood Cells Mol Dis · RCR 2.6 · 22 citations - Daratumumab for the treatment of refractory ANCA-associated vasculitis.
2023 · RMD Open · RCR 2.6 · 24 citations - High-affinity autoreactive plasma cells disseminate through multiple organs in patients with immune thrombocytopenic purpura.
2022 · J Clin Invest · RCR 2.6 · 34 citations - Emerging B and plasma cell-targeting immune therapies in idiopathic inflammatory myopathies.
2025 · Front Immunol · RCR 2 · 6 citations - New Therapies for the Treatment of Warm Autoimmune Hemolytic Anemia.
2022 · Transfus Med Rev · RCR 1.7 · 17 citations - Case Report: Resetting the Humoral Immune Response by Targeting Plasma Cells With Daratumumab in Anti-Phospholipid Syndrome.
2021 · Front Immunol · RCR 1.7 · 26 citations - Autoantibodies against CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) that impair glucose-induced insulin secretion in noninsulin- dependent diabetes patients.
1998 · J Clin Invest · RCR 1.7 · 72 citations - Human anti-CD38 autoantibodies raise intracellular calcium and stimulate insulin release in human pancreatic islets.
2001 · Diabetes · RCR 1.4 · 55 citations - Anti-CD38 autoimmunity in patients with chronic autoimmune thyroiditis or Graves' disease.
2001 · Clin Exp Immunol · RCR 1.4 · 51 citations - Autoantibodies to CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) in Caucasian patients with diabetes: effects on insulin release from human islets.
1999 · Diabetes · RCR 1.4 · 57 citations - Autoimmunity to CD38 and GAD in Type I and Type II diabetes: CD38 and HLA genotypes and clinical phenotypes.
2002 · Diabetologia · RCR 1.2 · 51 citations - Plasma Cell Directed Therapy for Immune Thrombotic Thrombocytopenic Purpura (iTTP).
2022 · Transfus Med Rev · RCR 1.1 · 11 citations - Increased CD38 expression in T cells and circulating anti-CD38 IgG autoantibodies differentially correlate with distinct cytokine profiles and disease activity in systemic lupus erythematosus patients.
2013 · Cytokine · RCR 1 · 40 citations - Antibody-mediated retinal pericyte injury: implications for diabetic retinopathy.
2012 · Invest Ophthalmol Vis Sci · RCR 1 · 30 citations - Renal manifestations of MGUS.
2024 · Hematology Am Soc Hematol Educ Program · RCR 0.8 · 4 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.13
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.06
- DepMap mean gene effect
- 0.01
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- apoptotic signaling pathway
- artery smooth muscle contraction
- B cell proliferation
- B cell receptor signaling pathway
- female pregnancy
- long-term synaptic depression
- negative regulation of apoptotic process
- negative regulation of bone resorption
- negative regulation of DNA-templated transcription
- negative regulation of neuron projection development
- nicotinate metabolic process
- positive regulation of B cell proliferation
- positive regulation of cell growth
- positive regulation of cytosolic calcium ion concentration
- positive regulation of DNA-templated transcription
- positive regulation of insulin secretion
- positive regulation of vasoconstriction
- response to estradiol
- response to hydroperoxide
- response to hypoxia
- response to interleukin-1
- response to progesterone
- response to retinoic acid
- response to xenobiotic stimulus
- signal transduction
Molecular functions
- identical protein binding
- NAD+ nucleosidase activity, cyclic ADP-ribose generating
- phosphorus-oxygen lyase activity
- transferase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads CD38 as an antibody target. Whether an autoantibody or antibody against CD38 could matter depends on whether native CD38 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
CD38 is annotated at the cell surface, where native CD38 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label CD38 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...